From: Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
Marker expression | Patients (n) | Patients (%) | Median survival (months) | 5-Year survival (%) | P |
---|---|---|---|---|---|
Skp2, <60 years, N = 99 | |||||
Low | 52 | 53 | NR | 71 | 0.074 |
High | 38 | 38 | 67 | 56 | |
Missing | 9 | 9 | |||
Skp2, ≥60 years, N = 94 | |||||
Low | 57 | 61 | 80 | 57 | 0.188 |
High | 29 | 31 | 36 | 42 | |
Missing | 8 | 9 | |||
ER, <60 years, N = 99 | |||||
Low | 55 | 56 | 127 | 59 | 0.197 |
High | 40 | 40 | NR | 67 | |
Missing | 4 | 4 | |||
ER, ≥60 years, N = 94 | |||||
Low | 57 | 61 | 80 | 55 | 0.293 |
High | 32 | 34 | 52 | 44 | |
Missing | 5 | 5 | |||
PGR, <60 years, N = 99 | |||||
Low | 63 | 64 | NR | 67 | 0.488 |
High | 34 | 34 | NR | 55 | |
Missing | 2 | 2 | |||
PGR, ≥60 years, N = 94 | |||||
Low | 69 | 73 | 91 | 57 | 0.043 |
High | 23 | 24 | 39 | 32 | |
Missing | 2 | 2 |